EMA Application withdrawn: Aplidin (plitidepsin) — Pharma Mar S.A.

View source ↗

Summary

The EMA has withdrawn the marketing authorization application for Aplidin (plitidepsin) by Pharma Mar S.A. for the treatment of multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Aplidin (plitidepsin)

Snippet

Status: Application withdrawn. Therapeutic area: Multiple Myeloma. MAH: Pharma Mar S.A.. Orphan medicine